financetom
Business
financetom
/
Business
/
Expect 40-50% revenue growth in FY24: Paras Defence & Space Technologies
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Expect 40-50% revenue growth in FY24: Paras Defence & Space Technologies
May 17, 2023 3:18 AM

Paras Defence & Space Technologies reports a steady fourth quarter with revenues 6 percent higher at Rs 65 crore. Earnings before interest, tax, depreciation and amortization declined 2 percent to Rs 17 crore. Operating profit margin at 26.4 percent stood 240 bps lower than 28.8 percent clocked in same quarter last year. Net profits, although jumped 5 percent in the fourth quarter of financial year 2022-23.

Share Market Live

NSE

The current order book is in excess of Rs 550 crore and will start building further in the next quarter. Amit Mahajan, Paras Defence & Space Technologies, in an interaction with CNBC-TV18 on May 17 expects 40 to 50 percent revenue growth in FY24. This is double of the 20 percent revenue growth clocked in FY23. The high revenue growth of FY24 is supported by a large order book. The margins are expected to be at similar levels or marginally better than FY23.

Also read: Paras Defence signs MoU MeiTY Research Lab for development of various technologies

Drones contribute less than 20 percent of company's order book. Furthermore, the company had received DGCA Type Certificate for agricultural drones. "Our technology in agri drones is much superior than the other agri drones available in market" Mahajan said. The company is manufacturing agri drones in-house and hence have been able to clock healthy margins in this segment. Paras Aerospace is expected to clock better growth than Paras Defence in FY24.

Exports are expected to contribute 10 to 20 percent of the company's revenues and by FY25, drones shall contribute 25 percent of total revenues.

Paras Defence & Space Technologies stock is 1 percent lower at noon on Wednesday and has fallen 13 percent in past one year.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Trilogy Metals Signs At-The-Market Equity Distribution Agreement
Trilogy Metals Signs At-The-Market Equity Distribution Agreement
May 27, 2025
07:27 AM EDT, 05/27/2025 (MT Newswires) -- Trilogy Metals ( TMQ ) on Tuesday said signed an equity distribution agreement with BMO Nesbitt Burns, BMO Capital Markets and Cantor Fitzgerald for an at-the-market equity program. The company said the distribution agreement will allow it to distribute up to US$25 million or the equivalent in Canadian dollars of its common shares....
Uranium Royalty Up Nearly 4% in U.S. Pre-market After Aberdeen Royalty Purchase
Uranium Royalty Up Nearly 4% in U.S. Pre-market After Aberdeen Royalty Purchase
May 27, 2025
07:24 AM EDT, 05/27/2025 (MT Newswires) -- Uranium Royalty ( UROY ) traded 3.9% higher at last look on Tuesday in Nasdaq pre-market trading as it agreed to acquire a 2% gross overriding royalty on Forum Energy Metals' ( FDCFF ) Aberdeen uranium project in Nunavut for $1 million. Under the terms, Forum retains the right to repurchase 0.5% of...
US FDA places clinical hold on Rocket Pharma's gene therapy trial
US FDA places clinical hold on Rocket Pharma's gene therapy trial
May 27, 2025
May 27 (Reuters) - The U.S. Food and Drug Administration placed a clinical hold on Rocket Pharmaceuticals' ( RCKT ) gene therapy trial due to a serious event in one patient, the company said on Tuesday. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved